Stock Ratings / Health Care / MGRX / dividends

NIVF (22) CCEL (64) PARK (49) VMD (69) ⌘ Pro Terminal →

Mangoceuticals Inc. (MGRX) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.25 -1.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.25

Mangoceuticals Inc. (MGRX) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $5.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.25 (-0.45%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MGRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY MGRX SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (38% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 32.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.42-31% Next Q

Q2 (-2Q)

Grade E$0.29-20.7% Next Q

Q3 (-1Q)

Grade E$0.23+8.7% Next Q

Current

Grade E$0.25-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MGRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MGRX currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.38) and Max Pain ($0.26) forces dealer call-delta covering toward $2.53.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MGRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MGRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MGRX)

✓Walkthrough of MGRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MGRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.47%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.26H $0.26L $0.23C $0.25VOL 521.7K

RES: $0.51SUP: $0.21SMA50: $0.38SMA200: $0.41

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MGRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MGRX Butterfly Map → + Track MGRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -26.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MGRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MGRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MGRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MGRX)

Health Care Rank #856 of 1016 ⚔️ NIVF vs MGRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MGRX vs. NIVF, CCEL, PARK, VMD)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Mangoceuticals Inc. (MGRX) ranks #856 by composite RQD confidence (34/100, grade E) and #935 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. VMD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with MGRX at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MGRX ACTIVE Mangoceuticals Inc.	E	34/100	—	54.9%	-35.0%	-1.47%	$5.7M	Benchmark Subject
NIVF NewGenIvf Group Limited (Class A)	E	22/100	—	—	-32.8%	-5.00%	$11.3M	/nivf-vs-mgrx →
CCEL Cryo-Cell International Inc.	C	64/100	—	—	18.2%	+1.17%	$41.8M	/ccel-vs-mgrx →
PARK Park Dental Partners Inc.	D	49/100	—	—	—	-2.79%	$95.4M	/park-vs-mgrx →
VMD Viemed Healthcare Inc.	C+	69/100	24.6x	57.5%	13.0%	-0.40%	$379.0M	/vmd-vs-mgrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001938046

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mangoceuticals Inc. (MGRX) reported GAAP revenue of $456.0K (-26.0% vs. FY2024 revenue of $615.9K , and -37.7% cumulative change since FY2023) , GAAP net income of -$20.6M, operating cash flow of -$5.9M, and free cash flow of -$5.9M (-20.3% YoY). On the balance sheet, MGRX closed FY2025 with $16.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$456.0K	-$20.6M	-$5.9M	-$5.9M	$16.1M	—
FY2024 (FY)	2024-12-31	$615.9K	-$8.7M	-$4.9M	-$4.9M	$15.4M	—
FY2023 (FY)	2023-12-31	$731.5K	-$9.2M	-$7.0M	-$7.0M	—	—

3. MGRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MGRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Mangoceuticals Inc. (NASDAQ: MGRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.25 (-1.47% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MGRX ranks #856 in composite RQD confidence.

How does MGRX compare to NIVF and CCEL in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), MGRX carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 54.9%, and ROIC of -35.0%. By comparison, NIVF (NewGenIvf Group Limited (Class A)) holds a E grade (22/100 RQD, P/E N/A, ROIC -32.8%, cap $11.3M) and CCEL (Cryo-Cell International Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 18.2%, cap $41.8M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MGRX?

Per MGRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001938046), Mangoceuticals Inc. generated $456.0K in revenue (-26.0% YoY), -$20.6M in net income, and -$5.9M in free cash flow against $16.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MGRX trading relative to its 50-day, 200-day, and 52-week technical levels?

MGRX last traded at $0.25 (-1.47% on volume of 234,027 shares), positioning the stock -34.21% below its 50-day simple moving average ($0.38) and -39.02% below its 200-day simple moving average ($0.41). Across its 52-week range of $0.16 to $2.41, MGRX sits at the 4.0% percentile with a 14-day RSI of 32.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.28).

MGRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does MGRX pay a dividend and is it safe?

Mangoceuticals Inc. (MGRX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: MGRX RQD Cockpit MGRX 12M Forecast MGRX Earnings & Move MGRX Dividends & DRIP MGRX Insiders & 13F MGRX Whale Options MGRX Profit Sankey MGRX News & Why